Cefpodoxime

Sold as Orelox-junior, Cepodem, Cefpodoxime unimed, Adco loxime, Cefpodoxime adco, Orchid-cefpodoxime, Dynacef, Orelox, Sandoz cefpodoxime, Oropod, Oreoxal

C₁₅H₁₇N₅O₆S₂427.50 g/mol

(6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Drag to rotate. Structure from PubChem CID 6335986.

Loading Wikipedia summary

Registration

Applicants: 8
Registrations: 19
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Equity Pharmaceutical (Pty) Ltd	Orelox-junior, Orelox	100, 200	270564, A380406, Z0007	S4	None
Ranbaxy Pharmaceutical (Pty) Ltd	Cepodem	40 mg/5 ML, 100, 200	360225, 360226, 360227	S4	None
Unimed Healthcare (Pty) Ltd	Cefpodoxime unimed	40 mg/5 ml, 100	360228, 360230	S4	None
MSQ Pharma (Pty) Ltd	Adco loxime	200	360229	S4	None
Adcock ingram limited	Cefpodoxime adco	40 mg/5ml, 100, 200	420387, 420388, 420389	S4	None
Orchid Pharmaceuticals SA (Pty) LtdCancelled	Orchid-cefpodoxime	100 mg	430012	S4	None
Pharma Dynamics (Pty) Ltd	Dynacef	5 ml, 100 mg	431084, 440012	S4	PI PIL
Sandoz South Africa (Pty) Ltd2 of 4 cancelled	Sandoz cefpodoxime, Oropod, Oreoxal	40 mg/5 ml, 100	A390397, A390398, A400734, A400735	S4	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Orelox-junior EACH 5 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO 40 mg CEFPODOXIME	Not listed	27056427/20.1.1/0564	Registered	S4	None
Cepodem 100 tablets EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100Tablets	36022536/20.1.1/0225	Registered	S4	None
Cepodem 200 tablets EACH TABLET CONTAINS: CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 200,0 mg	200Tablets	36022636/20.1.1/0226	Registered	S4	None
Cepodem suspension 40 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 40,0 mg	40 mg/5 MLSuspension	36022736/20.1.1/0227	Registered	S4	None
Cefpodoxime 100 unimed EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100	36022836/20.1.1/0228	Registered	S4	None
Adco loxime 200 tablets EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 200,0 mg	200Tablets	36022936/20.1.1/0229	Registered	S4	None
Cefpodoxime 40 mg/5 ML suspension unimed EACH 5,0 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 40,0 mg	40 mg/5 mlSuspension	36023036/20.1.1/0230	Registered	S4	None
Cefpodoxime 40 mg/5ml adco EACH 5,0 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 40,0 mg	40 mg/5ml	42038742/20.1.1/0387	Registered	S4	None
Cefpodoxime 100 adco EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100	42038842/20.1.1/0388	Registered	S4	None
Cefpodoxime 200 adco EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 200,0 mg	200	42038942/20.1.1/0389	Registered	S4	None
Orchid-cefpodoxime 100 MG EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100 mg	43001243/20.1.1/0012	Cancelled	S4	None
Dynacef suspension EACH 5,0 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 40,0 mg	5 mlPowder for oral suspension	43108443/20.1.1/1084Approved 6 December 2024	Registered	S4	PI PIL
Dynacef 100 MG EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100 mg	44001244/20.1.1/0012	Registered	S4	None
Orelox 200 EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 200,0 mg	200	A380406A38/20.1.1/0406	Registered	S4	None
Sandoz cefpodoxime 40 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 40,0 mg	40 mg/5 ml	A390397A39/20.1.1/0397	Registered	S4	None
Sandoz cefpodoxime 100 EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100	A390398A39/20.1.1/0398	Cancelled	S4	None
Oropod 40 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 40,0 mg	40 mg/5 ml	A400734A40/20.1.1/0734	Registered	S4	None
Oreoxal 100 EACH TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO CEFPODOXIME 100,0 mg	100	A400735A40/20.1.1/0735	Cancelled	S4	None
Orelox 100 EAHC TABLET CONTAINS CEFPODOXIME PROXETIL EQUIVALENT TO 100 mg CEFPODOXIME	100	Z0007Z/20.1.1/7	Registered	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Cefpodoxime proxetil equivalent to cefpodoxime

S4: Cefpodoxime
Consolidated Schedules 06 July 2026, line 5733

Pharmacological class: Broad and medium spectrum antibiotics. (class 20.1.1)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Dynacef suspension, Pharma Dynamics (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsDynacef suspension, Pharma Dynamics (Pty) Ltd Patient information leaflet (PIL)For patients and carersDynacef suspension, Pharma Dynamics (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background